;PMID: 2266390
;source_file_2942.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..36] = [t:0..36]
;1)sentence:[e:42..118] = [t:42..118]
;2)section:[e:122..228] = [t:122..228]
;3)section:[e:232..301] = [t:232..301]
;4)sentence:[e:305..461] = [t:305..461]
;5)sentence:[e:463..680] = [t:463..680]
;6)sentence:[e:681..805] = [t:681..805]
;7)sentence:[e:806..953] = [t:806..953]
;8)sentence:[e:954..1129] = [t:954..1129]
;9)sentence:[e:1130..1220] = [t:1130..1220]
;10)sentence:[e:1221..1278] = [t:1221..1278]
;11)sentence:[e:1279..1453] = [t:1279..1453]
;12)section:[e:1457..1501] = [t:1457..1501]

;section 0 Span:0..36
;J Nucl Med.  1990 Dec;31(12):1945-9.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..6] Nucl) (NNP:[7..10] Med) (.:[10..11] .)
        (CD:[13..17] 1990) (CC:[18..25] Dec;31-LRB-) (CD:[25..27] 12)
        (-RRB-:[27..28] -RRB-) (CD:[28..34] :1945-) (CD:[34..36] 9.)))

;sentence 1 Span:42..118
;SPECT quantitation of iodine-131 concentration in phantoms and human tumors.
(SENT
  (NP-HLN
    (NP (NN:[42..47] SPECT) (NN:[48..60] quantitation))
    (PP (IN:[61..63] of)
      (NP (NN:[64..74] iodine-131) (NN:[75..88] concentration)))
    (PP (IN:[89..91] in)
      (NP
        (NP (NNS:[92..100] phantoms))
        (CC:[101..104] and)
        (NP (JJ:[105..110] human) (NNS:[111..117] tumors))))
    (.:[117..118] .)))

;section 2 Span:122..228
;Israel O, Iosilevsky G, Front D, Bettman L, Frenkel A, Ish-Shalom S, Steiner
;M,  Ben-Harush M, Kolodny GM.
(SEC
  (FRAG (NNP:[122..128] Israel) (NNP:[129..130] O) (,:[130..131] ,)
        (NNP:[132..142] Iosilevsky) (NNP:[143..144] G) (,:[144..145] ,)
        (NNP:[146..151] Front) (NNP:[152..153] D) (,:[153..154] ,)
        (NNP:[155..162] Bettman) (NNP:[163..165] L,) (NNP:[166..173] Frenkel)
        (NNP:[174..175] A) (,:[175..176] ,) (NNP:[177..187] Ish-Shalom)
        (NNP:[188..189] S) (,:[189..190] ,) (NNP:[191..198] Steiner)
        (NNP:[199..201] M,) (NNP:[203..213] Ben-Harush) (NNP:[214..216] M,)
        (NNP:[217..224] Kolodny) (NNP:[225..227] GM) (.:[227..228] .)))

;section 3 Span:232..301
;Department of Nuclear Medicine, Rambam Medical Center, Haifa, Israel.
(SEC
  (FRAG (NNP:[232..242] Department) (IN:[243..245] of) (NNP:[246..253] Nuclear)
        (NNP:[254..262] Medicine) (,:[262..263] ,) (NNP:[264..270] Rambam)
        (NNP:[271..278] Medical) (NNP:[279..285] Center) (,:[285..286] ,)
        (NNP:[287..292] Haifa) (,:[292..293] ,) (NNP:[294..300] Israel)
        (.:[300..301] .)))

;sentence 4 Span:305..461
;The validity of SPECT measurement of iodine-131 (131I) concentration was
;tested  in vitro in phantoms and in vivo by measuring bladder urine
;concentrations.
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[305..308] The) (NN:[309..317] validity))
      (PP (IN:[318..320] of)
        (NP
          (NP (NN:[321..326] SPECT) (NN:[327..338] measurement))
          (PP (IN:[339..341] of)
            (NP
              (NML
                (NML (NN:[342..352] iodine-131))
                (NML (-LRB-:[353..354] -LRB-) (NN:[354..358] 131I)
                     (-RRB-:[358..359] -RRB-)))
              (NN:[360..373] concentration))))))
    (VP (VBD:[374..377] was)
      (VP
        (VP (VBN:[378..384] tested)
          (NP-1 (-NONE-:[384..384] *))
          (ADVP=2 (FW:[386..388] in) (FW:[389..394] vitro))
          (PP (IN:[395..397] in)
            (NP (NNS:[398..406] phantoms))))
        (CC:[407..410] and)
        (VP
          (ADVP=2 (FW:[411..413] in) (FW:[414..418] vivo))
          (PP-MNR (IN:[419..421] by)
            (S-NOM
              (NP-SBJ (-NONE-:[421..421] *))
              (VP (VBG:[422..431] measuring)
                (NP (NN:[432..439] bladder) (NN:[440..445] urine)
                    (NNS:[446..460] concentrations))))))))
    (.:[460..461] .)))

;sentence 5 Span:463..680
;Phantom studies comparing known and SPECT measured concentrations showed a
;good  correlation for 131I (r = 0.98, s.e.e. = 20.94 counts/voxel) for
;phantoms of 25  to 127 cc and concentrations of 0.13 to 9.5 microCi/cc.
(SENT
  (S
    (NP-SBJ
      (NP (NN:[463..470] Phantom) (NNS:[471..478] studies))
      (VP (VBG:[479..488] comparing)
        (NP (VBN:[489..494] known)
          (NML-1 (-NONE-:[494..494] *P*)))
        (CC:[495..498] and)
        (NP
          (ADJP (NN:[499..504] SPECT) (VBN:[505..513] measured))
          (NML-1 (NNS:[514..528] concentrations)))))
    (VP (VBD:[529..535] showed)
      (NP
        (NP (DT:[536..537] a) (JJ:[538..542] good) (NN:[544..555] correlation))
        (PP (IN:[556..559] for)
          (NP (NN:[560..564] 131I))))
      (PRN (-LRB-:[565..566] -LRB-)
        (FRAG
          (S
            (NP-SBJ (NN:[566..567] r))
            (VP (SYM:[568..569] =)
              (NP (CD:[570..574] 0.98))))
          (,:[574..575] ,)
          (S
            (NP-SBJ (NN:[576..582] s.e.e.))
            (VP (SYM:[583..584] =)
              (NP
                (NP (CD:[585..590] 20.94) (NNS:[591..597] counts))
                (PP (SYM:[597..598] /)
                  (NP (NN:[598..603] voxel)))))))
        (-RRB-:[603..604] -RRB-))
      (PP (IN:[605..608] for)
        (NP
          (NP
            (NP (NNS:[609..617] phantoms))
            (PP (IN:[618..620] of)
              (NP
                (QP (CD:[621..623] 25) (TO:[625..627] to) (CD:[628..631] 127))
                (NN:[632..634] cc))))
          (CC:[635..638] and)
          (NP
            (NP (NNS:[639..653] concentrations))
            (PP (IN:[654..656] of)
              (NP
                (NP
                  (QP (CD:[657..661] 0.13) (TO:[662..664] to)
                      (CD:[665..668] 9.5))
                  (NN:[669..676] microCi))
                (PP (SYM:[676..677] /)
                  (NP (NN:[677..679] cc)))))))))
    (.:[679..680] .)))

;sentence 6 Span:681..805
;The in vivo, in vitro  correlation of 131I concentrations in the urine was
;also good (r = 0.98, s.e.e.  = 0.677 microCi/cc).
(SENT
  (S
    (NP-SBJ
      (NP (DT:[681..684] The)
        (ADJP
          (ADJP (FW:[685..687] in) (FW:[688..692] vivo))
          (,:[692..693] ,)
          (ADJP (FW:[694..696] in) (FW:[697..702] vitro)))
        (NN:[704..715] correlation))
      (PP (IN:[716..718] of)
        (NP (NN:[719..723] 131I) (NNS:[724..738] concentrations)))
      (PP (IN:[739..741] in)
        (NP (DT:[742..745] the) (NN:[746..751] urine))))
    (VP (VBD:[752..755] was)
      (ADJP-PRD (RB:[756..760] also) (JJ:[761..765] good))
      (PRN (-LRB-:[766..767] -LRB-)
        (FRAG
          (S
            (NP-SBJ (NN:[767..768] r))
            (VP (SYM:[769..770] =)
              (NP (CD:[771..775] 0.98))))
          (,:[775..776] ,)
          (S
            (NP-SBJ (NN:[777..783] s.e.e.))
            (VP (SYM:[785..786] =)
              (NP
                (NP (CD:[787..792] 0.677) (NN:[793..800] microCi))
                (PP (SYM:[800..801] /)
                  (NP (NN:[801..803] cc)))))))
        (-RRB-:[803..804] -RRB-)))
    (.:[804..805] .)))

;sentence 7 Span:806..953
;Quantitative SPECT was used to calculate the effective  half-life and
;dosimetry of radioiodine in 12 sites of thyroid carcinoma in seven 
;patients.
;[916..933]:malignancy-type:"thyroid carcinoma"
(SENT
  (S
    (NP-SBJ-1 (JJ:[806..818] Quantitative) (NN:[819..824] SPECT))
    (VP (VBD:[825..828] was)
      (VP (VBN:[829..833] used)
        (NP-1 (-NONE-:[833..833] *))
        (S
          (NP-SBJ (-NONE-:[833..833] *))
          (VP (TO:[834..836] to)
            (VP (VB:[837..846] calculate)
              (NP
                (NP
                  (NP (DT:[847..850] the) (JJ:[851..860] effective)
                      (JJ:[862..866] half) (HYPH:[866..867] -)
                      (NN:[867..871] life))
                  (CC:[872..875] and)
                  (NP (NN:[876..885] dosimetry)))
                (PP (IN:[886..888] of)
                  (NP (NN:[889..900] radioiodine))))
              (PP-LOC (IN:[901..903] in)
                (NP
                  (NP (CD:[904..906] 12) (NNS:[907..912] sites))
                  (PP (IN:[913..915] of)
                    (NP (JJ:[916..923] thyroid) (NN:[924..933] carcinoma)))))
              (PP-LOC (IN:[934..936] in)
                (NP (CD:[937..942] seven) (NNS:[944..952] patients))))))))
    (.:[952..953] .)))

;sentence 8 Span:954..1129
;SPECT was also used to determine the dosimetry of [131I]MIBG 
;(metaiodobenzylguanidine) in two patients with carcinoid, two with 
;neuroblastoma, and one with pheochromocytoma.
;[1063..1072]:malignancy-type:"carcinoid"
;[1084..1097]:malignancy-type:"neuroblastoma"
;[1112..1128]:malignancy-type:"pheochromocytoma"
(SENT
  (S
    (NP-SBJ-1 (NN:[954..959] SPECT))
    (VP (VBD:[960..963] was)
      (ADVP (RB:[964..968] also))
      (VP (VBN:[969..973] used)
        (NP-1 (-NONE-:[973..973] *))
        (S-PRP
          (NP-SBJ (-NONE-:[973..973] *))
          (VP (TO:[974..976] to)
            (VP (VB:[977..986] determine)
              (NP
                (NP (DT:[987..990] the) (NN:[991..1000] dosimetry))
                (PP (IN:[1001..1003] of)
                  (NP (NN:[1004..1014] -LSB-131I-RSB-MIBG)
                    (PRN (-LRB-:[1016..1017] -LRB-)
                      (NP (NN:[1017..1040] metaiodobenzylguanidine))
                      (-RRB-:[1040..1041] -RRB-)))))
              (PP (IN:[1042..1044] in)
                (NP
                  (NP
                    (NP (CD:[1045..1048] two) (NNS:[1049..1057] patients))
                    (PP (IN:[1058..1062] with)
                      (NP (NN:[1063..1072] carcinoid))
                      (,:[1072..1073] ,)))
                  (NP
                    (NP (CD:[1074..1077] two))
                    (PP (IN:[1078..1082] with)
                      (NP (NN:[1084..1097] neuroblastoma))))
                  (,:[1097..1098] ,) (CC:[1099..1102] and)
                  (NP
                    (NP (CD:[1103..1106] one))
                    (PP (IN:[1107..1111] with)
                      (NP (NN:[1112..1128] pheochromocytoma)))))))))))
    (.:[1128..1129] .)))

;sentence 9 Span:1130..1220
;The radiation dose for thyroid  carcinoma metastases varied between 6.3 and
;276.9 rad/mCi.
;[1153..1171]:malignancy-type:"thyroid  carcinoma"
;[1172..1182]:malignancy-clinical-stage:"metastases"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1130..1133] The) (NN:[1134..1143] radiation)
          (NN:[1144..1148] dose))
      (PP (IN:[1149..1152] for)
        (NP
           (JJ:[1153..1160] thyroid) (NN:[1162..1171] carcinoma)
          (NNS:[1172..1182] metastases))))
    (VP (VBD:[1183..1189] varied)
      (PP (IN:[1190..1197] between)
        (NP
          (NP
            (QP (CD:[1198..1201] 6.3) (CC:[1202..1205] and)
                (CD:[1206..1211] 276.9))
            (NN:[1212..1215] rad))
          (PP (SYM:[1215..1216] /)
            (NP (NN:[1216..1219] mCi))))))
    (.:[1219..1220] .)))

;sentence 10 Span:1221..1278
;The dose from MIBG  varied between 13.4 and 57.8 rad/mCi.
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1221..1224] The) (NN:[1225..1229] dose))
      (PP (IN:[1230..1234] from)
        (NP (NN:[1235..1239] MIBG))))
    (VP (VBD:[1241..1247] varied)
      (PP (IN:[1248..1255] between)
        (NP
          (NP
            (QP (CD:[1256..1260] 13.4) (CC:[1261..1264] and)
                (CD:[1265..1269] 57.8))
            (NN:[1270..1273] rad))
          (PP (SYM:[1273..1274] /)
            (NP (NN:[1274..1277] mCi))))))
    (.:[1277..1278] .)))

;sentence 11 Span:1279..1453
;These results indicate the validity of  quantitative SPECT for in vivo
;measurement of 131I and the need to measure the  concentration of 131I in
;individual human tumor sites.
(SENT
  (S
    (NP-SBJ (DT:[1279..1284] These) (NNS:[1285..1292] results))
    (VP (VBP:[1293..1301] indicate)
      (NP
        (NP
          (NP (DT:[1302..1305] the) (NN:[1306..1314] validity))
          (PP (IN:[1315..1317] of)
            (NP
              (NP (JJ:[1319..1331] quantitative) (NN:[1332..1337] SPECT))
              (PP (IN:[1338..1341] for)
                (NP
                  (NP
                    (ADJP (FW:[1342..1344] in) (FW:[1345..1349] vivo))
                    (NN:[1350..1361] measurement))
                  (PP (IN:[1362..1364] of)
                    (NP (NN:[1365..1369] 131I))))))))
        (CC:[1370..1373] and)
        (NP (DT:[1374..1377] the) (NN:[1378..1382] need)
          (S
            (NP-SBJ (-NONE-:[1382..1382] *))
            (VP (TO:[1383..1385] to)
              (VP (VB:[1386..1393] measure)
                (NP
                  (NP (DT:[1394..1397] the) (NN:[1399..1412] concentration))
                  (PP (IN:[1413..1415] of)
                    (NP (NN:[1416..1420] 131I))))
                (PP-LOC (IN:[1421..1423] in)
                  (NP (JJ:[1424..1434] individual) (JJ:[1435..1440] human)
                      (NN:[1441..1446] tumor) (NNS:[1447..1452] sites)))))))))
    (.:[1452..1453] .)))

;section 12 Span:1457..1501
;PMID: 2266390 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1457..1461] PMID) (::[1461..1462] :) (CD:[1463..1470] 2266390)
        (NN:[1471..1472] -LSB-) (NNP:[1472..1478] PubMed) (::[1479..1480] -)
        (NN:[1481..1488] indexed) (IN:[1489..1492] for)
        (NNP:[1493..1501] MEDLINE-RSB-)))
